DNA RNA and Cells

30 Jan 2020 Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
30 Jan 2020 Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
30 Jan 2020 European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
30 Jan 2020 Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
29 Jan 2020 Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
29 Jan 2020 Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
27 Jan 2020 TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123
25 Jan 2020 Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
25 Jan 2020 Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens™
25 Jan 2020 Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV
22 Jan 2020 Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
22 Jan 2020 Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
22 Jan 2020 Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
22 Jan 2020 PDC*line Pharma raises €20 million in Series B financing round
21 Jan 2020 Biotech start-up Seekyo raises €800k with leverage from French Tech Seed Fund
17 Jan 2020 GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
17 Jan 2020 First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
15 Jan 2020 Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
15 Jan 2020 UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
15 Jan 2020 NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
14 Jan 2020 Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
13 Jan 2020 Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
13 Jan 2020 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
13 Jan 2020 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
13 Jan 2020 BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up